Cytomegalovirus retinitis in patients of non-Hodgkin’s lymphoma: clinical presentations and outcomes
Tóm tắt
Cytomegalovirus (CMV) retinitis in patients with Non-Hodgkin’s Lymphoma (NHL) can occur even in the presence of high CD 4 counts and can behave differently when compared to CMV retinitis in human immunodeficiency (HIV) patients. It, therefore, becomes important to understand its varied presentations and the challenges in management of these cases. The aim of this study was to analyse the various patterns of presentations and outcomes of CMV Retinitis in patients with NHL. A retrospective chart review of seven eyes of four patients of NHL presenting with CMV retinitis between June 2017 and May 2020 was done. Clinical patterns of CMV Retinitis, CD4 counts at the time of presentation and the duration of treatment along with recurrences and time for recurrence of retinitis were assessed. Granular or indolent retinitis (6 out of 7 eyes) was the commonest form of CMV retinitis in patients of NHL. Three patients had a presenting CD4 count above 150 cells/mm3 and none of them were below 50 cells/mm3. Floaters were the commonest presenting complaint. All patients had vitritis and majority of the patients (3 out of 4) had anterior chamber (AC) inflammation. Two out of the 4 patients had a recurrence (mean time 33.8 days) after stopping the maintenance phase of ganciclovir and one patient had significant myelosuppression related to oral valganciclovir which required discontinuation of the drug. CMV retinitis in NHL patients is usually of an indolent or granular type and can occur even in the presence of high CD4 counts as compared to patients with HIV. These patients may require a long term maintenance in view of frequent recurrences after discontinuation of treatment.
Tài liệu tham khảo
Carmichael A (2012) Cytomegalovirus and the eye. Eye Lond Engl 26:237–240
Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griths P (2019) Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol 29(3):e2034. https://doi.org/10.1002/rmv.2034
Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A (2018) Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol 36(2):381–391. https://doi.org/10.1002/hon.2453
Fuller R, Strauss D, Steinberg A, Rana M, Keyzner A, Dunn D, Jacobs SE (2019) A lymphoma patient with cytomegalovirus retinitis and post-autologous hematopoietic cell transplantation immune reconstitution uveitis: a case report and review of the literature. Transpl Infect Dis 21(4):e13099. https://doi.org/10.1111/tid.13099
Carbone J (2016) The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 100(Supplement 3S):S11–S18. https://doi.org/10.1097/TP.0000000000001095
Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP (2012) Meinert CL; studies of the ocular complications of AIDS research group. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 153(6):1016–1024. https://doi.org/10.1016/j.ajo.2011.11.014
Jabs DA, Nussenblatt RB (2005) Rosenbaum JT; standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516. https://doi.org/10.1016/j.ajo.2005.03.057
Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92(4):467–471. https://doi.org/10.1016/S0161-6420(85)34001-0
Pollard RB, Egbert PR, Gallagher JG, Merigan TC (1980) Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside. Ann InternMed 93(5):655–664. https://doi.org/10.7326/0003-4819-93-5-655
Nasir MA, Jaffe GJ (1996) Cytomegalovirus retinitis associated with Hodgkin's disease. Retina. 16(4):324–327. https://doi.org/10.1097/00006982-199616040-00008
Kang HM (2017) CMV retinitis in patients with DLBCL. J Retina 2(2):97–100. https://doi.org/10.21561/jor.2017.2.2.97
Tyagi M, Ambiya V, Mathai A, Narayanan R (2015) Atypical cytomegalovirus retinitis in non-Hodgkin's lymphoma. BMJ Case Rep 2015:bcr2015210812
Pathanapitoon K, Tesavibul N, Choopong P, Boonsopon S, Kongyai N, Ausayakhun S, Kunavisarut P, Rothova A (2013) Clinical manifestations of cytomegalovirus-associated posterior uveitis and panuveitis in patients without human immunodeficiency virus infection. JAMA Ophthalmol 131(5):638–645. https://doi.org/10.1001/jamaophthalmol.2013.2860
Munro M, Yadavalli T, Fonteh C, Arfeen S, Lobo-Chan AM (2019) Cytomegalovirus Retinitis in HIV and Non-HIV Individuals. Microorganisms 8(1):pii–E55
Ho M, Invernizzi A, Zagora S, Tsui J, Oldani M, Lui G, McCluskey P, Young AL (2019) Presenting features, treatment and clinical outcomes of cytomegalovirus retinitis: non-HIV patients vs HIV patients. Ocul Immunol Inflamm 5:1–8
DerzkoDzulynsky LA, Berger AR, Berinstein NL (1998) Cytomegalovirus retinitis and lowgrade nonHodgkin’s lymphoma: case report and review of the literature. Am J Hematol 57(3):228–232. https://doi.org/10.1002/(SICI)1096-8652(199803)57:3<228::AID-AJH9>3.0.CO;2-X
Chawla R, Venkatesh P, Garg SP, Mandal S, Tewari HK (2005) Cytomegalovirus retinitis in a patient with non-Hodgkin's lymphoma: a diagnostic dilemma. Eur J Ophthalmol 15(1):153–157. https://doi.org/10.1177/112067210501500127
Svozílková P, Heissigerová J, Brichová M, Kalvodová B, Dvořák J, Ríhová E (2013) A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma. Virol J 10(1):18. https://doi.org/10.1186/1743-422X-10-18
Gooi P, Farmer J, Hurley B, Brodbaker E (2008) Cytomegalovirus retinitis mimicking intraocular lymphoma. Clin Ophthalmol 2(4):969–971. https://doi.org/10.2147/opth.s4213
Zhao Y, Shao Q, Peng G (2020) Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol Immunol 17(1):27–35. https://doi.org/10.1038/s41423-019-0344-8
Xia A, Zhang Y, Xu J, Yin T, Lu XJ (2019) T cell dysfunction in Cancer immunity and immunotherapy. Front Immunol 10:1719. https://doi.org/10.3389/fimmu.2019.01719
Karavellas MP, Azen SP, MacDonald JC, Shufelt CL, Lowder CY, Plummer DJ, Glasgow B, Torriani FJ, Freeman WR (2001) Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina. 21(1):1–9. https://doi.org/10.1097/00006982-200102000-00001
Jacobsen T, Sifontis N (2010) Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 67(17):1417–1425. https://doi.org/10.2146/ajhp090424
Holbrook JT, Colvin R, van Natta ML, Thorne JE, Bardsley M, Jabs DA (2011) Studies of Ocular Complications of AIDS (SOCA) Research Group. Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis. Am J Ophthalmol 152(4):628–637.e1